Affiliation:
1. University of Liverpool
2. AstraZeneca UK Ltd
Abstract
Abstract
Translational approaches can benefit post-marketing drug safety surveillance through the growing availability of systems pharmacology data. Here, we propose a novel Bayesian framework for identifying drug-drug interaction (DDI) signals and differentiating between individual drug and drug combination signals. This framework is coupled with a systems pharmacology approach for automated biological plausibility assessment. Integrating statistical and biological evidence, our method achieves a 16.5% improvement (AUC: from 0.620 to 0.722) with drug-target-adverse event (AE) associations, 16.0% (AUC: from 0.580 to 0.673) with drug enzyme, and 15.0% (AUC: from 0.568 to 0.653) with drug transporter information. Applying this approach to detect potential DDI signals of QT prolongation and rhabdomyolysis within the FDA Adverse Event Reporting System (FAERS), we emphasize the significance of systems pharmacology in enhancing statistical signal detection in pharmacovigilance. Our study showcases the promise of data-driven biological plausibility assessment in the context of challenging post-marketing DDI surveillance.
Publisher
Research Square Platform LLC
Reference50 articles.
1. Drug interactions—principles, examples and clinical consequences;Cascorbi I;Dtsch. Arztebl. Int.,2012
2. Adverse drug reactions as cause of admission to hospital;Pirmohamed M;BMJ Br. Med. J.,2004
3. Drug interaction studies: Study design, data analysis, and implications for dosing and labeling;Huang SM;Clinical Pharmacology and Therapeutics,2007
4. W. Quantitative signal detection using spontaneous ADR reporting;Bate A;Pharmacoepidemiology and Drug Safety,2009
5. Opportunities and Challenges of Using Big Data to Detect Drug-Drug Interaction Risk;Quinney SK;Clin. Pharmacol. Ther.,2019